title: An upcoming drug for onychomycosis: Tavaborole.
abstract: Fungal infection of the nail as well as nail bed is termed as 'onychomycosis'. It is caused by dermatophytes, non-dermatophytic fungal species and yeasts like Candida albicans. It is traditionally treated by topical antifungals, systemic agents like ketoconazole, griseofulvin, itraconazole, fluconazole, etc. Chemical avulsion or surgical removal of nail can also be tried to treat this disease. In spite of all these treatment options available, podiatrists were always in search of an ideal drug molecule with lesser side effects and which may improve the patient compliance. This exhaustive search led to the discovery of a better antifungal agent, known as "Tavaborole." A systematic literature search was carried out using databases such as PubMed, Cochrane Reviews, Google Scholar, etc. Detailed information about onychomycosis and tavaborole was gathered. Tavaborole is the first oxaborole antifungal agent approved by FDA in July 2014. It is marketed under the trade name "Kerydin." It acts by inhibiting protein synthesis in the fungus. It inhibits an enzyme known as cytosolic leucyl-transfer RNA synthetase, or LeuRS, which plays a key role in fungal essential protein synthesis. Dermatitis at the site of topical application, erythema, exfoliation and ingrowing toe nail has been reported in 1% of subjects. Tavaborole may offer a promising role in the treatment of onychomycosis and may compell podiatrists to offer its use in onychomycosis. The present study describes about chemical nature, mechanism of action and two completed phase 3 clinical trial findings of Tavaborole.
authors.affiliation: Department of Pharmacology, NIMS Medical College, Jaipur, Rajasthan, India.
authors.forename: Neha
authors.initials: N
authors.lastname: Sharma
authors.affiliation: Department of General Surgery, Jawaharlal Nehru Medical College, Ajmer, Rajasthan, India.
authors.forename: Dhruva
authors.initials: D
authors.lastname: Sharma
keywords: Clinical trial; onychomycosis; tavaborole
references.citation: Indian J Med Microbiol. 2008 Apr-Jun;26(2):108-16
references.pmid: 18445944
references.citation: J Med Chem. 2006 Jul 27;49(15):4447-50
references.pmid: 16854048
references.citation: J Am Acad Dermatol. 1996 Sep;35(3 Pt 2):S2-5
references.pmid: 8784302
references.citation: J Am Podiatr Med Assoc. 2007 May-Jun;97(3):195-202
references.pmid: 17507527
references.citation: J Foot Ankle Res. 2011 Dec 04;4:26
references.pmid: 22136082
references.citation: J Dermatol. 2010 Feb;37(2):137-9
references.pmid: 20175847
references.citation: J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S57-69
references.pmid: 11051135
references.citation: J Cutan Med Surg. 2014 May-Jun;18(3):151-5
references.pmid: 24800702
references.citation: J Clin Aesthet Dermatol. 2014 Jul;7(7):10-8
references.pmid: 25053979
references.citation: Future Microbiol. 2014;9(11):1243-50
references.pmid: 25437186
references.citation: Clin Microbiol Rev. 1998 Jul;11(3):415-29
references.pmid: 9665975
references.citation: J Eur Acad Dermatol Venereol. 2006 Nov;20(10):1188-93
references.pmid: 17062029